trial

A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia

NCTId NCT07615426
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Recruiting
Enrollment 64 (estimated)
Sponsored by Janssen, L.P. - Investigator Initiated Studies Program
Primary completion 2027-06-21
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Recruiting
Enrollment
64 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2026-03-02
Primary completion
2027-06-21
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Aticaprant

Sponsors

Janssen, L.P. - Investigator Initiated Studies ProgramLead Sponsor

Sites

8 total
Garden Grove, United StatesAtlanta, United StatesChicago, United StatesKalamazoo, United StatesCedarhurst, United StatesStaten Island, United StatesAustin, United StatesRichardson, United States

Facts & assertions

4 sourced
Enrollment
64
Phase
PHASE1
Primary Completion Date
2027-06-21
Status
RECRUITING
relationships
The graph out of here
drug
Aticaprant
drug
lead_sponsor
Janssen, L.P. - Investigator Initiated Studies Program
company
indication
Schizophrenia
indication
Schizophrenia
indication